data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Geovax Labs

(NASDAQ:GOVX)

Intraday

$1.48

0.01[0.68%]

15 minutes delayed

Perks Buy Compare Brokers

$1.48

0.01[0.68%]

Last update: 7:01PM Get Real Time Here

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Geovax Labs Stock (NASDAQ:GOVX)

Geovax Labs Stock (NASDAQ: GOVX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 11, 2024

WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga Newsdesk - Apr 11, 2024, 10:09AM

Friday, April 05, 2024

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Apr 5, 2024, 8:09AM

Thursday, March 28, 2024

GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress
Benzinga Newsdesk - Mar 28, 2024, 9:06AM

Friday, March 01, 2024

GeoVax Labs Inc Files For Mixed Shelf Of Up To $100M
Benzinga Newsdesk - Mar 1, 2024, 4:16PM

Thursday, February 29, 2024

Geovax Labs: Q4 Earnings Insights
Benzinga Insights - Feb 29, 2024, 4:10PM
Geovax Labs Q4 2023 GAAP EPS $(3.940) Misses $(2.780) Estimate
Benzinga Newsdesk - Feb 29, 2024, 4:08PM
Earnings Scheduled For February 29, 2024
Benzinga Insights - Feb 29, 2024, 5:15AM

Wednesday, February 28, 2024

Earnings Outlook For Geovax Labs
Benzinga Insights - Feb 28, 2024, 2:02PM

Friday, February 23, 2024

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Avi Kapoor - Feb 23, 2024, 7:34AM

Friday, February 16, 2024

Geovax Labs On Feb 16, Received Letter From Nasdaq Stating Co To Have Regained Compliance With Nasdaq Listing Requirements
Benzinga Newsdesk - Feb 16, 2024, 4:05PM

Tuesday, February 13, 2024

GeoVax Announces Multiple Actions By Global Patent Offices Strengthening The Company's Intellectual Property Assets; Intellectual Property Assets Strengthened For Cancer Immunotherapy Program And For Marburg Virus And HIV Vaccines
Benzinga Newsdesk - Feb 13, 2024, 9:05AM

Tuesday, February 06, 2024

GeoVax Reports Interim Data From Phase 2 Clinical Trial Of GEO-CM04S1 As Universal Covid-19 Vaccine Booster
Benzinga Newsdesk - Feb 6, 2024, 9:02AM

Wednesday, January 31, 2024

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk - Jan 31, 2024, 8:55AM

Tuesday, January 30, 2024

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk - Jan 30, 2024, 7:50PM

Monday, January 29, 2024

GeoVax Announces 1-for-15 Reverse Stock Split To Regain Compliance With Nasdaq Minimum Bid Requirement
Benzinga Newsdesk - Jan 29, 2024, 9:01AM

Wednesday, January 24, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jan 24, 2024, 8:05AM

Thursday, January 04, 2024

GeoVax Announces Gedeptin Patient Enrollment Closure For Phase 1/2 Clinical Trial Among Advanced Head And Neck Cancer Patients
Benzinga Newsdesk - Jan 4, 2024, 9:10AM

Wednesday, January 03, 2024

GeoVax Announces Issuance of Malaria Vaccine Patent, Patent Covers Multiple Component Vaccine For Both Prevention And Treatment
Benzinga Newsdesk - Jan 3, 2024, 9:00AM

Wednesday, December 27, 2023

GeoVax Labs And 2 Other Stocks Under $2 Insiders Are Buying
Avi Kapoor - Dec 27, 2023, 8:55AM

Tuesday, December 19, 2023

GeoVax Expands Rights Under NIH COVID-19 License To Include Mpox And Smallpox; Financial Terms Of The License Agreement Were Not Disclosed
Benzinga Newsdesk - Dec 19, 2023, 9:05AM

Friday, December 08, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Dec 8, 2023, 4:30PM
Reported Earlier, "WHO 'Very Worried' About Spread Of Mpox In DRC" - Reuters News
Benzinga Newsdesk - Dec 8, 2023, 12:31PM

Thursday, December 07, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Dec 7, 2023, 8:07AM

Tuesday, November 28, 2023

GeoVax COVID-19 Vaccine Clinical Data Presented At World Vaccine Congress
Benzinga Newsdesk - Nov 28, 2023, 9:05AM

Tuesday, November 14, 2023

Progress On GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented At Vaccines Summit 2023
Benzinga Newsdesk - Nov 14, 2023, 9:21AM

Monday, November 13, 2023

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target
Benzinga Newsdesk - Nov 13, 2023, 7:48AM

Wednesday, November 08, 2023

Geovax Labs: Q3 Earnings Insights
Benzinga Insights - Nov 8, 2023, 4:10PM
Geovax Labs Q3 2023 GAAP EPS $(0.32) Misses $(0.24) Estimate
Benzinga Newsdesk - Nov 8, 2023, 4:10PM
Earnings Scheduled For November 8, 2023
Benzinga Insights - Nov 8, 2023, 4:21AM

Tuesday, November 07, 2023

Geovax Labs Earnings Preview
Benzinga Insights - Nov 7, 2023, 1:01PM

Monday, October 30, 2023

GeoVax Commences Site Expansion For Phase 2 Trial Of Next-Generation Covid-19 Vaccine
Benzinga Newsdesk - Oct 30, 2023, 9:16AM

Tuesday, October 24, 2023

GeoVax Provides Update On Clinical And Operational Progress Toward Transformative Opportunities
Benzinga Newsdesk - Oct 24, 2023, 9:06AM

Monday, October 09, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Oct 9, 2023, 5:31PM
HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target
Benzinga Newsdesk - Oct 9, 2023, 10:56AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Oct 9, 2023, 9:06AM
GeoVax Receives Notice Of Allowance For Marburg Vaccine Patent; Application Number 17/584,231 Titled "Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) And Matrix Protein (VP40)."
Benzinga Newsdesk - Oct 9, 2023, 9:01AM

Thursday, October 05, 2023

GeoVax Receives Notice Of Allowance For HIV Vaccine Patent
Benzinga Newsdesk - Oct 5, 2023, 9:01AM

Thursday, September 28, 2023

GeoVax Labs And 3 Other Stocks Under $1 Insiders Are Buying
Lisa Levin - Sep 28, 2023, 8:29AM

Tuesday, September 26, 2023

GeoVax Secures Multi-Product License For ProBioGen's AGE1.CR.pIX Suspension Cell Line To Bolster MVA-Based Vaccine Development
Benzinga Newsdesk - Sep 26, 2023, 9:23AM

Wednesday, September 20, 2023

GeoVax COVID-19 Vaccine Data Presented At Keystone Symposia Conference
Benzinga Newsdesk - Sep 20, 2023, 9:01AM

Tuesday, September 19, 2023

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody And Cellular Immunity In Immunocompromised Patients
Benzinga Newsdesk - Sep 19, 2023, 9:06AM

Friday, September 15, 2023

'MPOX: Chinese Health Officials Step Up Control Measures As Cases Rise' - South China Morning Post
Benzinga Newsdesk - Sep 15, 2023, 9:13AM

Monday, September 11, 2023

GeoVax Completes Enrollment Of Phase 2 Trial For Next-Generation COVID-19 Vaccine Booster
Bill Haddad - Sep 11, 2023, 9:09AM

Thursday, August 31, 2023

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target
Benzinga Newsdesk - Aug 31, 2023, 4:19AM

Monday, August 28, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Aug 28, 2023, 9:06AM
GeoVax Receives Notice of Allowance For Patent Application No. 17/726,254 Titled "Compositions And Methods For Generating An Immune Response To Treat Or Prevent Malaria"
Benzinga Newsdesk - Aug 28, 2023, 9:02AM

Wednesday, August 23, 2023

'Holiday Warning To Anyone Heading To Spain Over New Outbreak Of Mpox' - The Sun
Happy Mohamed - Aug 23, 2023, 3:37PM

Tuesday, August 22, 2023

'Standing Recommendations For Mpox Issued By The Director-General Of The World Health Organization In Accordance With The International Health Regulations'
Happy Mohamed - Aug 22, 2023, 10:51AM
ADDvantage Technologies Group And 3 Other Stocks Under $1 Insiders Are Buying
Lisa Levin - Aug 22, 2023, 9:08AM

Friday, August 18, 2023

'CHP Investigates Two Confirmed Mpox Cases' - The Government Of The Hong Kong Special Administrative Region
Benzinga Newsdesk - Aug 18, 2023, 9:00AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved